desonide inn lowpotency topical corticosteroid antiinflammatory available since primarily used treat atopic dermatitis eczema seborrheic dermatitis contact dermatitis psoriasis adults children fairly good safety available cream ointment lotion foam tradename verdeso foam trade names creams lotions ointments include tridesilon desowen desonate group vi corticosteroid us classification second least potent group desonide prescription topical treatment redness swelling itching discomfort various skin conditions regardless vehicle used desonide applied times day times day skin conditions typically improve first two weeks treatment patients instructed use desonide minimum amount time necessary conditions safety desonide determined beyond weeks patients allergies corticosteroids like hydrocortisone prednisone use caution taking pharmacists prescribing physicians aware medication may contain inactive ingredients cause allergic reactions desonide used infection open wound treatment area systemic absorption topical corticosteroids produce adverse effects indication cushings syndrome hyperglycemia glycosuria observed patients receiving treatment stopping treatment reversible hypothalamicpituitaryadrenal hpa axis suppression potential glucocorticosteroid insufficiency possible cosyntropin laboratory test evaluate patients hpa axis hpa function reversed cessation treatment replacement another less potent corticosteroid glucocorticosteroid insufficiency occurs supplemental systemic corticosteroids may required side effects desonide requiring immediate contact prescribing physician side effects may go away body adjusts medication fda labeled desonide pregnancy category c desonide used pregnancy absolutely necessary currently unknown whether topical application desonide pass breast milk similar drugs taken orally seen pass breast milk prescribing doctor consulted prior breastfeeding desonide synthetic nonfluorinated corticosteroid topical corticosteroids antiinflammatory antipruritic vasoconstrictive properties mechanism properties however unclear dermal route following absorption skin corticosteroids follow pharmacokinetic pathways similarly intravenously administered corticosteroids mechanism corticosteroids thought induce phospholipase inhibitory proteins lipocortins lipocortins control biosynthesis inflammation mediators like prostaglandins leukotrienes lipocortins inhibit common precursor inflammation mediators arachidonic acid common medications causing minor negative drug interaction include insulin metformin common medications checked combination known create negative drug interaction include aspirin cymbalta duloxetine fish oil acetaminophen vitamin vitamin c vitamin desonide first introduced united states trade name tridesilon dome laboratories since discovery united states several countries introduced different brand names desonide including italy spain united kingdom germany fda first approved connetics corporation verdeso september shortly fda approved skinmedica inc hydrogel delivery vehicle october gel currently manufactured bayer healthcare pharmaceuticals inc whippany nj creams ointments lotions currently manufactured dpt laboratories ltd san antonio texas marketed galderma laboratories suppliers generic desonide include rebel distributors corp perrigo new york inc desonate approved fda following two major clinical trials randomized doubleblind placebocontrolled study enrolled pediatric patients ages months patient topically administered drug placebo two times day four weeks using investigator global severity score igss treatment considered successful week least two point decrease patient baseline igss clinical trial patients succeeded successful treatment desonate versus treated placebo clinical trial patients succeeded successful treatment desonate versus treated placebo fda approved tridesilon following treatments contact dermatitis rhus dermatitis eczema dermatitis discoid lupus erythematosus granuloma annulare seborrheic dermatitis polymorphous light eruption pruritus psoriasis lichen simplex atopic dermatitis lichen planus xerosis exfoliative recently late phase clinical trials completed evaluate treatments using desonide cream versus amino acid moisturizing patients eczema atopic dermatitis could enrolled study male female age randomized doubleblind active control study compared effects treatment creams twiceaday application clinical trial sponsored neostrata company inccitation needed research completed evaluate carcinogenic photococarcinogenic potential desonide additionally research completed determine effect current opportunities improvement learn risks benefits associated desonide first us patent desonide granted january patent topical antiinflammatory treatment using desonide patent defends suitability antiinflammatory treatment cutaneous disorders disruptions characterized skin inflammation andor hyperproliferative activity epidermis side effects mechanism action disclosed patent currently expired httpsenwikipediaorgwikidesonide